Funders › MA › Alzheimer's Disease Research Foundation › 2020
Grants paid by Alzheimer's Disease Research Foundation, tax year 2020
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
In tax year 2020, Alzheimer's Disease Research Foundation (EIN 52-2396428) reported 47 grants paid totaling $11,742,907. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2020
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2020 | Massachusetts General Hospital Boston, MA | A | $1,725,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202141319349300914 |
| 2020 | The Broad Institute Inc Cambridge, MA | A | $550,000 | paid | CIRCUITS: CONSORTIUM TO INFER REGULATORY CIRCUITS AND UNCOVER INNOVATIVE THERAPEUTIC STRATEGIES PRODUCTION GROUP | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $450,000 | paid | CHARACTERIZING GUT MICROBIOME SYNERGY WITH EMPHASIS ON MYCOBIOME AND ITS IMPACT ON ALZHEIMER'S DISEASE (AD) PATHOLOGY IN AD MOUSE MODEL | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $402,500 | paid | 3DDS CONSORTIUM: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $350,000 | paid | MICROBES AND ALZHEIMER'S DISEASE: METAGENOMICS ON SALIVA, CSF, BLOOD AND BRAIN | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE (YEAR 2) CHOI & WRANN | 202141319349300914 |
| 2020 | Boston Childrens Hospital Boston, MA | A | $300,000 | paid | NEUROIMFLAMMATION CONSORTIUM: UNDERSTANDING THE CONSEQUENCES OF NON-CODING AD RISK ALLELES ON MICROGLIA FUNCTION | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $300,000 | paid | APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION (YEAR 3) | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $259,366 | paid | COMPREHENSIVE ANALYSES OF CHRONIC EFFICACY STUDIES WITH GSM 776890 FOR SUBMISSION OF THE PRE-IND BROCHURE TO THE FDA PRIOR TO PRE-IND MEETING AND IND FILING FOR THE SAD/MAD PHASE I SAFETY/TOXICITY AND ULTIMATELY FOR PHASE II AND PHASE III EFFICACY CLINICAL TRIALS TO SUPPORT THE NDA | 202141319349300914 |
| 2020 | The University of California Irvine Irvine, CA | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: EXAMINING THE ROLE OF HUMAN MICROGLIA IN THE TRANSITION BETWEEN PARENCHYMAL AND VASCULAR BETAAMYLOID PATHOLOGY | 202141319349300914 |
| 2020 | New York University School of Medicine New York, NY | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTIONS (YEAR 2) | 202141319349300914 |
| 2020 | Mayo Clinic Jacksonville Jacksonville, FL | A | $250,000 | paid | APOE CONSORTIUM: COUNTERACTING PATHOGENIC EVENTS IN AD WITH PERIPHERAL OR CENTRAL APOE (YEAR 3) | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: USING EPIGENETICS TO CHARACTERIZE THE REGULATION OF CELLULAR STATES IN MICROGLIA THAT CONTRIBUTE TO ALZHEIMER'S DISEASE PATHOLOGY | 202141319349300914 |
| 2020 | University of Southern California Los Angeles, CA | A | $250,000 | paid | MOLECULAR SIGNATURES OF APOE-MEDIATED BLOOD-BRAIN BARRIER DYSFUNCTION CAUSING NEURONAL AND SYNAPTIC DYSFUNCTION | 202141319349300914 |
| 2020 | The Rockefeller University New York, NY | A | $250,000 | paid | APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE (YEAR 3) | 202141319349300914 |
| 2020 | Brigham and Women's Hospital Boston, MA | A | $250,000 | paid | THE ROLE OF APOE IN MICROGLIA REGULATIONS IN NEURODEGENERATION (YEAR 3) | 202141319349300914 |
| 2020 | Harvard College Boston, MA | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: ASSESSING THE LINKS BETWEEN THE MS4A RISK GENES, MICROGLIA, AND ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | University of Texas Southwestern Medical Center Dallas, TX | A | $250,000 | paid | MECHANISMS OF TAU PROPAGATION ACROSS THE PLASMA MEMBRANE | 202141319349300914 |
| 2020 | Mgh Neurology Reasearch Boston, MA | A | $250,000 | paid | CREATION OF FIBROBLAST/IPS CELL BANK TO FACILITATE PERIPHERAL/BRAIN COMPARISONS, AND ALLOW MOLECULAR INVESTIGATIONS INTO MOLECULAR MECHANISMS UNDERLYING DIFFERENCES IN DISEASE AGGRESSIVENESS (YEAR 1) | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $247,922 | paid | APOE CONSORTIUM: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS (YEAR 3) | 202141319349300914 |
| 2020 | University of Virginia Charlottesville, VA | A | $229,249 | paid | ADULT HUMAN INERONS: A NEXT GENERATION DRUG SCREENING PLATFORM FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | Duke University School of Medicine Durham, NC | A | $203,281 | paid | SEX DIFFERENCES IN ALZHEIMER'S DISEASE PROGRESSION: FRAMINGHAM HEART STUDY | 202141319349300914 |
| 2020 | Houston Methodist Hospital Foundation Houston, TX | A | $200,000 | paid | 3DDS CONSORTIUM: UNCOVERING THE MOLECULAR MECHANISMS OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | THE NEDD4-1 AND PKCA CONNECTION IN ALZHEIMER'S DISEASE (YEAR 1) | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $172,500 | paid | INVESTIGATING THE CONTRIBUTION OF ASTROCYTIC-DEPENDENT INFLAMMATION ON AMYLOID INDUCED TAU PATHOLOGY | 202141319349300914 |
| 2020 | University of North Carolina Chapel Hill Chapel Hill, NC | A | $172,500 | paid | SMALL MOLECULE ACTIVATORS OF PLC-Y2 AS NOVEL | 202141319349300914 |
| 2020 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | GUT MICROBIOTA, ENDOTHELIAL DYSFUNCTION AND TAU-MEDIATED COGNITIVE IMPAIRMENT | 202141319349300914 |
| 2020 | Yale University New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION (YEAR 2 OF 2) | 202141319349300914 |
| 2020 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | GENES TO THERAPIES (G2T) CENTRALIZED RESEARCH | 202141319349300914 |
| 2020 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | VHTS FOR CD33 INHIBITORS | 202141319349300914 |
| 2020 | Beth Israel Deaconess Medical Center Boston, MA | A | $172,500 | paid | CIRCUITS: INTERGRATING FUNCTIONAL MAPS TO DISCOVER MICRO RNA'S IN AD | 202141319349300914 |
| 2020 | Harvard College Boston, MA | A | $172,500 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE (YEAR 1) | 202141319349300914 |
| 2020 | Mayo Clinic Rochester, MN | A | $172,500 | paid | SENESCENT CELLS AND ALZHEIMER'S DISEASE (YEAR 2) | 202141319349300914 |
| 2020 | Wake Forest University Health Services Winstonsalem, NC | A | $172,500 | paid | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE INDUCTIONAND MAINTENANCE (YEAR 1) | 202141319349300914 |
| 2020 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $172,500 | paid | CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202141319349300914 |
| 2020 | Stanford University Stanford, CA | A | $172,500 | paid | A TRANSCRIPTIONAL REJUVENATION SIGNATURE FOR ALZHEIMER'S DISEASE | 202141319349300914 |
| 2020 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | 3DDS CONSORTIUM: PROTEOMICS OF ALZHEIMER'S DISEASE 3D CULTURES | 202141319349300914 |
| 2020 | Trustees of Tufts College Boston, MA | A | $172,500 | paid | IN VIVO CHARACTERIZATION OF A LOSS OF FUNCTION GGA3 RARE VARIANT ASSOCIATED WITH AD (YEAR 1) | 202141319349300914 |
| 2020 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 (YEAR 1) | 202141319349300914 |
| 2020 | University of Chicago Chicago, IL | A | $168,434 | paid | EFFECT OF GUT MICROBIOME DYSBIOSIS ON NEUROINFLAMMATION AND A-DEPOSITION: A LONGITUDINAL MICRO-PET STUDY IN ALZHEIMER'S TRANSGENIC MICE | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $143,750 | paid | PHARMACOLOGICALLY PROTECTING AND RESCUING SYNAPSES FROM BETA AMYLOID BY RAISING SYNAPTIC PSD-95 (YEAR 2) | 202141319349300914 |
| 2020 | The Salk Institute for Biological Studies La Jolla, CA | A | $115,000 | paid | CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202141319349300914 |
| 2020 | Albert Einstein College of Medicine Bronx, NY | A | $100,000 | paid | IMPROVING ALZHEIMERS DISEASE CLINICAL TRIALS DESIGN BY MACHINE LEARNING LABS | 202141319349300914 |
| 2020 | Amylyx Cambridge, MA | A | $100,000 | paid | UNDERSTANDING AND MIMICKING THE BIOLOGICAL EFFECTS OF THE PLCY2 P522R VARIANCE THAT PROTECT AGAINST AD | 202141319349300914 |
| 2020 | The University of California San Diego La Jolla, CA | A | $98,921 | paid | ABETA MEDIATED INHIBITION OF GAMMA-SECRETASE ACTIVITY INDUCES AD-RELEVANT CELLULAR PHENOTYPES(YEAR 2) | 202141319349300914 |
| 2020 | Washington University St Louis St Louis, MO | A | $21,984 | paid | CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOLOGICAL CONTINUUM (YEAR 1) | 202141319349300914 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.